Observational study finds prediabetes remission associated with 58% reduced cardiovascular risk — Evidence Review
Published in The Lancet Diabetes & Endocrinology, by researchers from King's College London, University Hospital Tuebingen
Researched by
— the AI search engine for science
Table of Contents
People with prediabetes who achieve remission—returning blood sugar to normal—may halve their risk of fatal heart events, according to research from King's College London. Most related studies agree that reversing prediabetes reduces both future diabetes and cardiovascular risk, although the degree of benefit and mechanisms remain debated.
- Several large studies and meta-analyses support that remission from prediabetes to normal glucose regulation is associated with reduced cardiovascular events and mortality, but some trials found lifestyle interventions alone did not always result in lower cardiovascular mortality 1 3 9 13.
- Evidence suggests that while lifestyle changes are effective for diabetes prevention, only those who achieve full glycemic normalization (prediabetes remission) experience substantial cardiovascular benefit, with this effect persisting over decades 3 5 9.
- Pharmacological and surgical interventions, such as metformin or bariatric surgery, may also lower cardiovascular risk in prediabetes, but the most pronounced legacy effects appear when prediabetes is fully reversed 4 7 9.
Study Overview and Key Findings
Prediabetes affects over a billion people worldwide and is a known risk factor for both type 2 diabetes and cardiovascular disease. While lifestyle modification has long been recommended, its direct impact on heart attack and mortality risk in prediabetes has been uncertain. The present study addresses this gap by analyzing long-term outcomes from two landmark diabetes prevention trials, focusing on whether achieving prediabetes remission (normalizing blood glucose) affects cardiovascular outcomes. This approach offers new insights into the long-term benefits of targeting glycemic normalization—not just delaying diabetes onset—as a central strategy in cardiovascular disease prevention.
| Property | Value |
|---|---|
| Organization | King's College London, University Hospital Tuebingen |
| Journal Name | The Lancet Diabetes & Endocrinology |
| Authors | Dr. Andreas Birkenfeld |
| Population | People with prediabetes |
| Methods | Observational Study |
| Outcome | Cardiovascular death, hospitalization for heart failure, heart attack |
| Results | Prediabetes remission linked to 58% lower cardiovascular risk. |
Literature Review: Related Studies
To place these findings in context, we searched the Consensus database, which aggregates over 200 million research papers. The following search queries were used to identify relevant studies:
- prediabetes remission cardiovascular risk reduction
- heart problems prediabetes reversal effects
- cardiovascular outcomes prediabetes intervention studies
| Topic | Key Findings |
|---|---|
| Does reversing prediabetes reduce cardiovascular events and mortality? | - Achieving remission from prediabetes to normal glucose regulation is associated with a lower long-term risk of cardiovascular events and mortality 3 5 9. - Earlier meta-analyses found that interventions can prevent diabetes, but effects on cardiovascular mortality and heart attacks in prediabetes have been inconsistent, with some studies showing benefits mainly for stroke 1 12. |
| How effective are lifestyle and pharmacological interventions? | - Intensive lifestyle modification (diet, exercise, weight loss) reduces progression to diabetes and improves risk factors, but impact on major cardiovascular outcomes is mixed 1 11 13. - Metformin and bariatric surgery can also reduce CVD risk, with surgical remission of diabetes showing particularly strong effects 4 13. |
| Is there a long-term or "legacy" effect of prediabetes remission? | - Remission from prediabetes to normal glucose regulation leads to persistent, decades-long reduction in cardiovascular risk, with benefits outlasting the initial intervention period 3 5 9. - Longer follow-up durations reveal more pronounced reductions in all-cause and cardiovascular mortality, especially in those who maintain remission 5 9. |
| What mechanisms underlie risk reduction in prediabetes remission? | - Lowering HbA1c (a marker of blood sugar) is closely linked to reduced major cardiovascular events, while heart failure risk reduction appears more related to bodyweight and class-specific drug effects (e.g., SGLT2 inhibitors) 7. - Restoring normal glucose regulation may prevent vascular complications by addressing underlying metabolic dysfunctions, though precise predictors and mechanisms remain under investigation 2 6 8. |
Does reversing prediabetes reduce cardiovascular events and mortality?
The new study's finding that remission from prediabetes is associated with markedly lower risks of cardiovascular death and heart failure is strongly supported by recent long-term analyses. These consistently show that returning to normal glucose regulation is linked to reduced rates of heart attacks, heart failure, and mortality in diverse populations, even after decades of follow-up. However, some earlier meta-analyses suggested that interventions delaying diabetes did not always translate to lower cardiovascular deaths, highlighting the importance of achieving full remission.
- Large-scale studies and meta-analyses confirm that prediabetes remission significantly reduces cardiovascular risk over the long term 3 5 9.
- Benefits are robust across different populations and study designs, including both Western and Asian cohorts 3 9.
- Some earlier reviews indicated that intervention benefits focused mainly on stroke rather than all forms of cardiovascular mortality 12.
- The magnitude of risk reduction appears greatest in those reaching and maintaining normal glucose levels, rather than just improving risk factors 3 5 9.
How effective are lifestyle and pharmacological interventions?
While lifestyle interventions are broadly effective for diabetes prevention and improving cardiovascular risk factors, their direct impact on actual heart attack or mortality outcomes in prediabetes has been less clear. Recent data suggest that only individuals who achieve true remission—rather than partial improvement—experience the most significant cardiovascular protection. Pharmacological agents like metformin, and surgical interventions such as bariatric surgery, also contribute to risk reduction, with the latter showing particularly high rates of disease remission.
- Intensive lifestyle changes reduce diabetes incidence and improve cardiovascular risk markers, but effects on hard outcomes (heart attacks, death) are inconsistent for all participants 1 11 13.
- Metformin is effective for diabetes prevention, especially in younger, high-risk populations, but did not significantly reduce major cardiovascular events in long-term trials 1 13.
- Bariatric surgery induces remission of diabetes and prediabetes, with substantial reductions in cardiovascular risk among obese patients 4.
- Individuals who achieve full normalization of blood glucose see the greatest, most lasting cardiovascular benefit 3 9.
Is there a long-term or "legacy" effect of prediabetes remission?
The evidence indicates that remission from prediabetes yields a strong and persistent protective effect against cardiovascular disease, even years after blood glucose normalization is first achieved. This "legacy effect" means that early, effective intervention may confer benefits that last well beyond the active intervention phase, especially in those who maintain remission over time.
- Long-term follow-up (20-30 years) shows halved risk of cardiovascular death or heart failure in people who achieve prediabetes remission 5 9.
- Benefits are more pronounced in women, younger individuals, and those with higher baseline cardiovascular risk 5.
- Duration of remission and length of follow-up are critical: the longer remission is maintained, the greater the reduction in mortality and cardiovascular events 5 9.
- These findings suggest that targeting remission, not just risk factor modification, may provide durable cardiovascular protection 3 5 9.
What mechanisms underlie risk reduction in prediabetes remission?
Several studies point to improved glycemic control (as measured by HbA1c) as a key driver of reduced cardiovascular events (such as heart attack and stroke), with additional benefits from weight loss and direct effects of certain antihyperglycemic medications. Nonetheless, the precise biological mechanisms remain under study, and predictors of who will achieve remission are not fully understood.
- Lowering HbA1c is closely tied to reduction in major cardiovascular events, but heart failure risk is more strongly related to bodyweight changes and specific drug effects (e.g., SGLT2 inhibitors) 7.
- Restoration of normal glucose regulation may prevent both microvascular and macrovascular complications by reversing underlying metabolic dysfunctions such as insulin resistance and inflammation 2 8.
- Early intervention is critical for maximizing long-term benefit, particularly before the onset of overt diabetes or established cardiovascular disease 5 8.
- Further research is needed to clarify which individuals are most likely to achieve and sustain remission, and through what mechanisms this translates to cardiovascular protection 2 8.
Future Research Questions
While the new findings provide compelling evidence for targeting prediabetes remission as a strategy to reduce cardiovascular risk, several important questions remain. Further studies are needed to clarify the best methods for achieving and sustaining remission, to identify which patient populations benefit most, and to better understand the mechanisms underlying the observed long-term protective effects.
| Research Question | Relevance |
|---|---|
| What are the most effective strategies for achieving sustained remission of prediabetes? | Identifying optimal interventions is crucial, as current evidence suggests full remission offers the greatest cardiovascular benefit, but not all approaches are equally effective in inducing lasting glycemic normalization 1 4 5 9. |
| Which patient populations derive the greatest cardiovascular benefit from prediabetes remission? | Determining which subgroups (e.g., by age, sex, baseline risk) benefit most can guide targeted prevention efforts and personalized interventions 5 9. |
| What are the mechanisms linking prediabetes remission to long-term cardiovascular risk reduction? | Understanding the biological pathways involved could inform novel therapies and help explain why remission leads to durable cardiovascular protection 2 7 8. |
| Does the method of remission (e.g. lifestyle vs pharmacological vs surgical) affect cardiovascular outcomes? | Comparing different intervention modalities could clarify whether certain approaches confer greater or more durable cardiovascular benefits and inform treatment guidelines 1 4 7 13. |
| How can we predict which individuals with prediabetes will achieve remission and maintain it long-term? | Developing predictive tools or biomarkers would help clinicians identify patients most likely to benefit from intensive intervention, maximizing the efficiency of prevention programs 8. |